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Abstract
Excessive adiposity (particularly visceral fat mass) increases the risks of developing metabolic syndrome. Women have
lower deposit of visceral fat than men, and this pattern becomes diminished postmenopausally, but the underlying
mechanism remains largely unknown. Here, we show that the gender difference in visceral fat distribution is
controlled by an estradiol–autophagy axis. In C57BL/6J and wild-type control mice, a higher visceral fat mass was
detected in the males than in the females, which was associated with lower expression of estrogen receptor α (ERα)
and more active autophagy in males vs. females. However, deletion of ERα normalized autophagy activity and
abolished the gender difference in visceral adiposity. In line with the adiposity-reducing effect of the ERα–autophagy
axis, we found that downregulation of ERα and increased autophagy activity were required for adipogenesis, while
induction of estradiol signaling dampened autophagy and drastically prevented adipogenesis. Mechanistically, the
estradiol-ERα signaling activated mTOR, which phosphorylated and inhibited ULK1, thereby suppressing autophagy
and adipogenesis. Together, our study suggests that the lower visceral adiposity in the females (vs. the males) arises
from a more active estradiol-ERα signaling, which tunes down autophagy and adipogenesis.
Introduction
White adipose (or fat) tissues (WAT) play a central role in
metabolic homeostasis through energy storage and endo-
crine functions1,2. It has been shown that fat depots at dis-
tinct anatomical (e.g., subcutaneous vs. visceral) locations
have intrinsic differences in hormone response, gene
expression, remodeling, and metabolism3–9. Excessive visc-
eral fat is associated with metabolic syndrome development
(e.g., insulin resistance) in animal models and humans,
whereas subcutaneous fat is benign or protective9–13.
Compared with women, men have more visceral fat14,15.
Intriguingly, visceral fat mass increases in post-menopausal
women (characteristic of reduced estrogen secretion), which
can be prevented by estrogen replacement therapy16,17.
These ﬁndings underscored an important role of estrogen
signaling in the regulation of fat development and distribu-
tion, yet the molecular mechanism remains largely elusive.
WAT mass development and maintenance are dependent
on adipocyte turnover. It was estimated that the rate of
adipocyte turnover was 10% per year in humans and 1–5%
per day in mice18,19. The overall adipocyte number in WAT
is balanced by adipogenesis (i.e., the differentiation of pre-
adipocyte into adipocytes) and adipocyte apoptosis18–20.
Emerging evidence suggests that autophagy, the major
intracellular degradation and remodeling system, regulates
both adipocyte differentiation and apoptosis21–23. Blockage of
autophagy through ablation of Atg5 or Atg7 substantially
prevents adipocyte differentiation and promotes adipocyte
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apoptosis, which signiﬁcantly reduces fat mass in mice21–23.
We and others have showed that autophagy is required to
maintain PPARγ and FSP27, the key regulators of adipocyte
differentiation and lipid droplet formation in fat cells24,25.
Suppression of autophagy downregulates PPARγ and FSP27,
concomitant with dampened adipocyte differentiation and
marginal lipid accumulation in the cells24,25. Therefore,
autophagy acts as a critical regulator of WAT remodeling
and maintenance.
Given the above-mentioned evidence that implies
estrogen and autophagy in WAT regulation, we asked the
question whether autophagy might interact with estrogen
signaling, and how it might link to the gender difference in
visceral adiposity. Here, we show that male mice had
higher visceral fat mass than the females, which was
associated with lower expression of estrogen receptors
(ERα) in the visceral adipose tissue. Activation of estradiol
(E2) signaling suppressed autophagy via an mTOR-ULK
pathway, which inhibited adipogenesis and was associated
with a lower visceral adiposity in the mice. However,
deletion of ERα normalized autophagy activity and gender-
dependent difference in visceral adiposity. Our data reveals
for the ﬁrst time an E2–ERα–autophagy axis that con-
tributes to the gender difference in visceral fat distribution.
Results
Female mice had lower visceral WAT (vWAT) mass than
male mice
A higher vWAT volume in men than women has been
observed across races14,15. To determine if mice have a
similar pattern of fat distribution, we examined C57BL/6J
at the age of 6–7 weeks (Fig. 1). As expected, the female
mice had lower body weight than males (average 15.4 g vs.
17.5 g, p < 0.05; Fig. 1a). The net weights of gonadal WAT
(the largest visceral fat depots in mice) and subcutaneous
WAT (inguinal fat depots, sWAT) were both lower in
female mice than in the males (Fig. 1b, c). However, after
normalization against the body weight only the vWAT
mass remained lower in females than in males (average
0.87 vs. 1.21%, p < 0.05; Fig. 1d), while the differences in
sWAT mass became indiscernible between the males and
females (average 0.45 vs. 0.49%, p= 0.14; Fig. 1e).
Therefore, the ratios of visceral fat to body weight (or
vWAT percentage) reveal a gender-dependent phenotype
in mice as observed previously in human subjects.
Autophagy activity in vWAT was lower in female than male
mice
Autophagosome formation is characterized by lipida-
tion of LC3 to form LC3-phospholipid conjugate (LC3-II),
which can be degraded by lysosomal hydrolase in auto-
lysosome26,27. In sWAT, steady-state LC3-II levels did not
differ between female and male mice (Fig. 2a, b). However,
a signiﬁcantly lower (50%, p < 0.01) steady-state LC3-II
was detected in vWAT from male mice vs. that from
female mice (Fig. 2c, d), suggesting that autophagic
degradation of LC3-II in vWAT was more active in the
males than in the females. To test this, we detected LC3-II
turnover (or autophagy ﬂux)25,27,28, by detecting the
accumulation of LC3-II after treating WAT explant cul-
tures with autophagy inhibitors baﬁlomycin A1 and leu-
peptin (BL) for 4 h. In line with the steady-state levels of
LC3-II in sWAT being indiscernible between the males
and females (Fig. 2a, b), autophagy ﬂux in sWAT did not
show signiﬁcant difference between the males and females
(Fig. 2e, f). However, the autophagy ﬂux in vWAT was
signiﬁcantly higher in the males (1.6-fold upregulated,
p < 0.05) than in the females (Fig. 2e, f). The turnover of
p62, which is selectively degraded by autophagy, further
validated the higher autophagy activity in vWAT from
male mice than that from female mice (Fig. 2g, h). These
data support the notion that increased LC3-II
turnover results in a reduced steady-state level of LC3-II
(Fig. 2c, d)26,29. Together, female mice had lower autop-
hagy activity in vWAT than the males.
Estrogen receptors were upregulated in vWAT from
females vs. males
E2 signaling is primarily funneled through ERα and
ERβ30. Compared with the males, the female mice had
similar expression of ERα and ERβ in sWAT (Fig. 3a, b).
However, vWAT had signiﬁcant lower protein levels of
ERα and ERβ in male mice than in female mice (Fig. 3c,
d), being 40% for ERα (p < 0.01) and 54% for ERβ (p <
0.05). Interestingly, the overall protein levels of ERβ in
vWAT appeared to be much lower than that of ERα for
both genders (Fig. 3c, d), suggesting that ERαmight play a
dominant role in mediating E2 actions in vWAT.
Adipogenesis was associated with downregulation of
estrogen receptors but upregulation of autophagy activity
The observation of lower expression of ER but higher
autophagy activity in the males vs. females (Figs. 2, 3)
prompted us to examine whether this reciprocal relation
exists in adipogenesis, the process that is critical for adi-
pose tissue development and maintenance31,32. As shown
in Fig. 4a and b, ERα was downregulated by 80% (p < 0.01)
and ERβ by 54% (p < 0.05) during adipogenesis, which was
characterized by drastic accumulation of lipid in the cells
(Fig. 4c). In addition, the downregulation of ERs was
associated with 81% (p < 0.0001) reduction in the steady-
state level of LC3-II (Fig. 4d, e). Autophagy ﬂux assays by
LC3-II turnover suggested that the differentiated adipo-
cytes had an autophagy activity 2.6-fold (p < 0.0001)
higher than the preadipocytes, which was further veriﬁed
by the turnover of p62 (Fig. 4f, g). These results recapi-
tulated the pattern observed in vWAT, where steady-state
level of LC3-II was reduced due to increased autophagy
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activity (Fig. 2)26,29. Importantly, the in vitro and in vivo
data work in concert to reveal a reciprocal relationship
between autophagy activity and ER levels.
Estradiol signaling suppressed autophagy and
adipogenesis
To examine whether E2 signaling per se regulate adi-
pocyte autophagy and adipogenesis, we treated 3T3L1
preadipocytes with or without E2 (0.1 μM) on day 0
through day 12, during which adipogenesis was induced
according to an established protocol (see Materials and
Methods)25,33–35. E2 treatment substantially increased the
accumulation of LC3-II (2.8-folds, p < 0.0001), as well as
p62 (1.6-fold, p < 0.05), the selective substrate of autop-
hagy for degradation (Fig. 5a, b)25,33,36. The E2-enhanced
accumulation of LC3-II and p62 was associated with
Fig. 1 Gender difference existed in the percentage of visceral but not subcutaneous fat. a The body weights of male and female mice at the
age of 6–7 weeks. b The net weights of visceral WAT from male and female mice. c The net weights of subcutaneous WAT from male and female
mice. d The percentage of visceral WAT from male and female mice, normalized against the body weights. e The percentage of subcutaneous WAT
from male and female mice, normalized by body weights. *p < 0.05; **p < 0.01; n.s. not signiﬁcant; n= 4–6
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reduced autophagy ﬂux (Fig. 5c, d), suggesting that E2
dampens autophagy activity. In addition, the E2-treated
cells were barely differentiated into mature adipocytes and
showed marginal lipid accumulation compared with
vehicle-treated cells (Fig. 5e). Likewise, treatment of
3T3L1 preadipocytes with the established autophagy
inhibitor BL almost completely prevented adipogenesis
(Fig. 5f). In addition, the presence of E2 or autophagy
inhibitor BL similarly inhibited autophagy and adipogen-
esis in primary stromal vascular cells isolated from vWAT
(Fig. 1s). Thus, E2 signaling suppresses adipogenesis at
least in part via autophagy inhibition.
Estradiol signaling suppressed autophagy via mTOR-ULK1
To explore the mechanism of E2 regulating autophagy,
we analyzed the interactions of E2 signaling and proteins
Fig. 2 Autophagy activities showed gender difference in visceral but not subcutaneous fat. a, b The steady-state protein levels of LC3 in
subcutaneous WAT, analyzed by Western blotting (a) and densitometry (b). c, d The steady-state protein levels of LC3 in visceral WAT, analyzed by
Western blotting (c) and densitometry (d). e–h Measurement of autophagy ﬂux in subcutaneous and visceral WAT. The WAT explant cultures were
incubated with and without autophagy inhibitor baﬁlomycin A1 (0.1 μM) and leupeptin (10 μg/ml) for 4 h, and the turnovers of LC3-II and p62 were
examined by Western blotting (e, g) and densitometry (f, h). In densitometric analyses, the band densities of investigated proteins were normalized
against that of GAPDH or β-actin, and the fold changes were calculated by taking the normalized density of female group as “1”. For autophagy ﬂux,
we ﬁrst normalized the band densities of LC3-II and p62 against that of GAPDH, then calculated the differences of normalized densities in the
presence vs. the absence of autophagy inhibitor; lastly, the differences were shown as fold changes by taking the female group as “1”. BL baﬁlomycin
A1 and leupeptin, M male, F female; *p < 0.05; **p < 0.01; n.s. not signiﬁcant; n= 3–4
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that are known to control autophagy, including ULK1,
beclin 1, Atg5, Atg7, and Atg1237–39. We found that
beclin 1 was upregulated during adipocyte differentiation,
but E2 treatment had marginal effect on beclin 1 level
(Fig. 2s, A–B). ULK1 was activated during adipogenesis,
because the mTOR-mediated inhibitory phosphorylation
of ULK1 at Ser 757 (p-ULK1Ser757) was signiﬁcantly
reduced37–39. However, E2 treatment suppressed ULK1
by increasing p-ULK1Ser757, concomitant with the acti-
vation of mTOR indicated by phosphorylation at Ser2448
(p-mTORSer2448) (Fig. 6a, b)37–41. These data suggest that
E2 signaling acts on ULK1 but not beclin 1, although both
proteins participate in autophagy initiation (i.e., formation
of the isolation membrane)37–39. Moreover, no discernible
change was detected in Atg5, Atg7, and Atg12-Atg5
conjugate, the proteins or components that regulate
membrane elongation37,39, during adipocyte differentia-
tion or during E2 treatment (Fig. 2s, A–B). These results,
along with the above observation that E2 suppressed
autophagy in adipocytes (Figs. 4–5), suggest that E2 may
regulate autophagy via the mTOR-ULK1 cascade.
To validate the E2/ER signaling-mTOR-ULK1 pathway
in vivo, we examined adipose tissues from male and
female C57BL/6J mice (Fig. 6c, d). In line with the females
having higher ER levels in vWAT than the males (Fig. 3),
the activating phosphorylation of mTOR (p-mTORSer2448)
was enhanced by 4.8-fold (p < 0.0001), and the mTOR-
mediated inhibition of ULK1 (p-ULK1Ser757) was 2.1-fold
stronger (p < 0.05; Fig. 6e, f). In sWAT, however, no sta-
tistically signiﬁcant difference was detected (Fig. 6c, d),
consistent with the male and the females showing com-
parable levels of ER in sWAT (Fig. 3). Notably, we did not
detect signiﬁcant difference in beclin 1, Atg5, Atg7, or
Atg12-Atg5 conjugate, between the male and the females
(Fig. 2s, C–D). Together, our in vitro and in vivo results
support the hypothesis that E2/ER signaling regulates
adipose autophagy via the mTOR-ULK1 pathway.
Ablation of ERα normalized autophagy activity and
abolished gender difference in visceral adiposity
ERα and ERβ have been shown to suppress or enhance
autophagy in different cancer cells42–46. To determine the
primary role player in the regulation of autophagy and
adipocyte differentiation, we treated 3T3L1 cells with
selective agonists of ERα (PPT) and ERβ (DPN)47,48. PPT
reduced autophagy activity and suppressed adipogenesis
but DPN had marginal effect, suggesting that ERα played
the dominant role (Fig. 3s). To validate this, we examined
autophagy and visceral adiposity in ERα knockout (KO)
mice (Fig. 7)49. As observed in the C57BL/6J mice, the
control (or wild-type, WT) females had higher expression
of ERα and stronger inhibition of ULK1 (p-ULK1Ser757) in
Fig. 3 The expression of estrogen receptors (ER) showed gender difference in visceral but not subcutaneous fat. a–b The protein levels of
ERα and ERβ in subcutaneous WAT, analyzed by Western blotting (a) and densitometry (b). c–d The protein levels of ERα and ERβ in visceral WAT,
analyzed by Western blotting (c) and densitometry (d). In densitometric analysis, the band densities of investigated proteins were normalized against
that of β-actin, and the fold changes were calculated by taking the normalized density of female group as “1”. *p < 0.05; **p < 0.01; n.s. not signiﬁcant;
n= 3–4
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Fig. 4 Adipogenesis was associated with downregulation of ER but upregulation of autophagy activity. a–b The protein levels of ERα and
ERβ in preadipocytes and mature (or differentiated) adipocytes, analyzed by Western blotting (a) and densitometry (b). DI differentiation induction. DI
+ represents differentiated 3T3L1 cells (mature adipocytes) harvested on day 12; DI− represents 3T3L1 cells without differentiation induction (i.e.,
preadipocytes) harvested on day 12. c Oil Red O staining to detect the differentiation of preadipocytes into mature adipocytes. On day 12, massive
lipid accumulation was detected in mature adipocytes but not in preadipocytes. d, e The steady-state protein levels of LC3 in preadipocytes and
mature adipocytes, analyzed by Western blotting (d) and densitometry (e) on day 12. f, g Measurement of autophagy ﬂux in preadipocytes and
mature adipocytes. On day 12, the cells were incubated in the presence or absence of autophagy inhibitor BL (baﬁlomycin A1 at 0.1 μM and
leupeptin at 10 μg/ml) for 4 h, and the turnovers of LC3-II and p62 were examined by Western blotting (f) and densitometry (g). In densitometric
analysis, the band densities of investigated proteins were normalized against that of GAPDH or β-actin, and the fold changes were calculated by
taking the normalized density of DI− group as “1”. For autophagy ﬂux analysis, we ﬁrst normalized the band densities of LC3-II and p62 against that
of β-actin, then calculated the differences of normalized densities in the presence vs. the absence of autophagy inhibitor; lastly, the differences were
shown as fold changes by taking the DI− group as “1”. BL baﬁlomycin A1 and leupeptin. *p < 0.05; **p < 0.01; ***p < 0.0001; n= 3–4
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Fig. 5 Activation of estrogen signaling suppressed autophagy and adipogenesis. a, b Estradiol (0.1 μM, days 0–12) increased the steady-state
protein levels of LC3 and p62 during 3T3L1 preadipocyte differentiation, analyzed by Western blotting (a) and densitometry (b). DI+ represents
3T3L1 cells with differentiation induction and harvested on day 12. c, d The presence of E2 (0.1 μM, days 0–12) reduced autophagy activity during
preadipocyte differentiation. On day 12, autophagy ﬂux was analyzed by Western blotting (c) and densitometry (d) after the cells were incubated
with and without autophagy inhibitor BL (baﬁlomycin A1 at 0.1 μM and leupeptin at 10 μg/ml) for 4 h. In densitometric analysis, the band densities of
investigated proteins were normalized against that of β-actin, and the fold changes were calculated by taking the normalized density of E2- group as
“1”. For autophagy ﬂux analysis, we ﬁrst normalized the band densities of LC3-II and p62 against that of β-actin, then calculated the differences of
normalized densities in the presence vs. the absence of autophagy inhibitor; lastly, the differences were shown as fold changes by taking the E2-
group as “1”. e The presence of E2 (0.1 μM, days 0–12) suppressed the differentiation of 3T3L1 preadipocytes, analyzed by Oil Red O staining on day
12. f The presence of autophagy inhibitor baﬁlomycin A1 (4 nM) and leupeptin (0.4 ng/ml) during days 0–12 recapitulated the effects of E2 on
adipogenesis, analyzed by Oil Red O staining on day 12. n= 3–4; *p < 0.05; **p < 0.01; ***p < 0.0001 (with E2 vs. without E2)
Tao et al. Cell Death and Disease  (2018) 9:309 Page 7 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
vWAT than the WT males, although sWAT showed no
gender difference in ERα and p-ULK1Ser757 (Fig. 7a, b).
However, KO of ERα reduced the inhibitory phosphor-
ylation of ULK1 (p-ULK1Ser757) in both sWAT and
vWAT, and, most importantly, it abolished the gender
difference in vWAT (Fig. 7a, b). Consistently, the gender-
dependent difference in autophagy ﬂux was diminished by
the KO of ERα in vWAT (Fig. 7c–d; Figs. 4s–5s). In line
with the enhanced autophagy (Fig. 7a–d; Figs. 4s–5s),
which was found to promote adipogenesis (Figs. 4–5;
Fig. 1s), the loss of ERα increased both sWAT and vWAT
masses in the ERα KO mice compared with the WT mice
(Fig. 7e–h). Furthermore, the gender difference in vWAT
mass was abolished by the ablation of ERα (Fig. 7f, h).
Therefore, the E2-ERα signaling cascade plays the central
role in the gender difference in visceral adiposity via
regulating autophagy.
Discussion
Increased visceral adiposity has been strongly associated
with higher risks of developing metabolic disorders9–13.
Females have lower visceral fat mass than males, but this
gender difference is diminished in older age groups
because post-menopausal women have increased visceral
adiposity; the age-related accumulation of visceral fat in
post-menopausal women is likely due to drastically
reduced estrogen levels14–17,50,51. Indeed, estrogen repla-
cement therapy prevents post-menopausal women from
excessive visceral adiposity, underlining estrogen signal-
ing as an important regulator of visceral distribution16,17.
Fig. 6 Estradiol-ER signaling regulated autophagy via mTOR-ULK1 pathway. a, b E2 (0.1 μM, days 0–12) induced the activating phosphorylation
of mTOR (Ser2448) and the mTOR-catalyzed inhibitory phosphorylation of ULK1 (Ser757), analyzed by Western blotting (a) and densitometry (b). DI+
represents 3T3L1 cells with differentiation induction and harvested on day 12, and DI− represents 3T3L1 cells without differentiation and harvested
on day 12. c, d The females and males showed comparable phosphorylation of mTOR (Ser2448) and ULK1 (Ser757), analyzed by Western blotting (c)
and densitometry (d). e, f The females showed signiﬁcantly stronger phosphorylation of mTOR (Ser2448) and ULK1 (Ser757) than the males, analyzed
by Western blotting (e) and densitometry (f). In densitometric analysis, the band densities of investigated proteins were normalized against that of
GAPDH or β-actin, and the fold changes were calculated by taking the normalized density of DI-E2- group (a and b) or female group (c–f) as “1”. *p <
0.05; **p < 0.01; ***p < 0.0001; n.s. not signiﬁcant; n= 3–4
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To understand the underlying mechanism, we investi-
gated the interaction between estrogen signaling and
autophagy, and its relation with adipogenesis and visceral
adiposity in mice. We found that female mice had lower
vWAT mass than males (Fig. 1), which was associated
with higher expression of ERs but lower activity of cell
Fig. 7 (See legend on next page.)
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remodeling via autophagy in females (Figs. 2–3). The
lower vWAT mass in females seemed to arise from E2-
signaling suppressed autophagy and adipogenesis
(Figs. 4–5, Fig. 1s). Adipogenesis was associated with
downregulation of ERs and increased autophagy activity
(Fig. 4, Fig. 1s). However, induction of E2 signaling
dampened autophagy and adipogenesis, and use of
established autophagy inhibitor BL recapitulated the
effects of E2 on adipogenesis (Fig. 5, Fig. 1s). These
ﬁndings suggest that the lower visceral adiposity in
females is due to a stronger E2 signaling that inhibits
autophagy and adipogenesis to a greater extent than in
males. Indeed, ablation of ERα normalized autophagy
activity and diminished the gender difference in visceral
adiposity (Fig. 7, Fig. 3s). Of note, the sWAT mass in
female mice was indiscernible from that in the males,
although in humans females have higher sWAT adiposity
than males52–54. The species similarity and disparity
between mice and humans highlights the importance of
carefully considering the strengths and limitations of
rodents as physiological models for humans55.
The role of estrogen signaling in metabolism and
adiposity has been extensively investigated56–62. However,
this is the ﬁrst study of E2 signaling in the regulation of
adipocyte autophagy. Our data suggests that E2 signaling
served as a suppressor of adipocyte autophagy (Figs. 4–7).
In particular, E2 induced the activation of mTOR, which
phosphorylated (p-ULK1Ser757) and thus deactivated
ULK1, the key components of autophagy initiation com-
plex (Fig. 6)37–39. In line with males showing lower levels
of ERs in vWAT, the inhibitory phosphorylation of ULK1
by mTOR was signiﬁcantly lower (2.1-fold, p < 0.05) than
that in females (Fig. 6). Moreover, ablation of ERα sig-
niﬁcantly mitigated (p-ULK1Ser757) and normalized the
gender difference in p-ULK1Ser757. Both in vitro and
in vivo evidence supports the existence of the E2/ER-
mTOR-ULK1 signaling cascade. However, further studies
are warranted to determine how E2 signaling activates
mTOR. In breast cancer cells it was shown that E2 might
activate mTOR via small GTPase Ras homolog enriched
in brain (Rheb), and it is still unclear how E2/ER signaling
interacts with Rheb63.
Our ﬁndings may shed light on the increased visceral
adiposity and metabolic syndrome (e.g., fatty liver) in
breast cancer patients receiving anti-estrogenic treat-
ment64,65. For instance, tamoxifen, a selective ER mod-
ulator that binds to ERs and suppresses estrogen action,
was found to signiﬁcantly increase body mass index (30.9
on average, indicative of obesity), visceral fat area, and
incidence of type 2 diabetes in women with breast can-
cer64. The E2–autophagy–adipogenesis axis identiﬁed in
this study may account, at least in part, for the tamoxifen-
induced visceral obesity in tamoxifen users. In laboratory
animals, hyperplasia (i.e., increased adipogenesis) can be
induced by removal of E2 (via ovariectomy) or ERα (via
genetic KO) which increases visceral fat mass and impairs
metabolism; by contrast, administration of E2 reduces
adiposity and improves metabolic homeostasis61,62,66,67.
Therefore, the effects of E2–autophagy axis on adiposity
and metabolic homeostasis should be taken into con-
sideration in future anti-estrogenic treatment of breast
cancer.
Taken together, our study provides the ﬁrst line of
evidence that E2/ER signaling mediates gender difference
in visceral adiposity by dampening autophagy and adi-
pogenesis via the mTOR-ULK1 pathway. The males have
distinctly lower expression of ER in visceral fat than the
females, thereby enhancing autophagy and adipogenesis
and leading to higher distribution of visceral fat in male
mice. Although ERβ cannot be excluded from the reg-
ulating process, ERα appears to play the dominant role
because deletion of ERα alone normalized the gender
differences in autophagy activity and visceral adiposity.
This study adds to the importance of considering the
gender perspective on the role of autophagy in human
diseases68. Given that nutrient signal also regulates
mTOR activity38, it would be of interest for future
investigation to depict how E2/ER interacts with nutrient
statuses (e.g., fasting or feeding with high-energy diet) in
the regulation of autophagy and adiposity.
(see ﬁgure on previous page)
Fig. 7 Ablation of ERα normalized gender difference in autophagy and visceral adiposity. a Knockout (KO) of ERα in sWAT-activated ULK1 by
de-phosphorylation at Ser757. b KO of ERα in vWAT-activated ULK1 by de-phosphorylation at Ser757, which diminished the gender difference in ERα
expression and p-ULK1 observed in the WT mice. c, d The vWAT in WT females had lower autophagy activity (LC-3II and p62 turnover) than that in
WT males (c), but KO of ERα abolished the gender difference (d). The representative Western blotting images were presented in Figs. 4s and 5s. In
densitometric analysis, the band densities of investigated proteins were normalized against that of GAPDH, and the fold changes were calculated by
taking the normalized density of male group as “1”. For autophagy ﬂux, we ﬁrst normalized the band densities of LC3-II and p62 against that of
GAPDH, then calculated the differences of normalized densities in the presence vs. the absence of autophagy inhibitor; lastly, the differences were
shown as fold changes by taking the male group as “1”. e–h WT males had higher vWAT mass than the WT females (f), but KO of ERα abolished the
gender difference (h). Overall, KO of ERα increased adiposity in both sWAT and vWAT, presumably due to the enhanced autophagy that promotes
adipogenesis. WT wild-type, KO knockout of ERα, M male, F female, WT/M wild-type males, WT/F wild-type females, KO/M knockout males, KO/F
knockout females; *p < 0.05; **p < 0.01; n.s. not signiﬁcant; n= 5–8
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Materials and methods
Mice
C57BL/6J mice were housed in plastic cages on a 12-h
light–dark photocycle and with free access to water and
regular chow diet as described previously25,34; at the age
of 6–7 week old, the mice were weighed and sacriﬁced for
tissue collection. The WT and global ERα KO mice were
obtained by breeding heterozygous males to females as
described previously49; at the age of 12–16 week old, the
WT and ERα KO mice were weighed and sacriﬁced for
tissue collection. The WAT pads were collected and
weighed quickly before SVF isolation, explant culture for
autophagy ﬂux analysis, or snap freezing in liquid nitro-
gen. Animal use procedures followed the National Insti-
tutes of Health guidelines and were approved by the
Virginia Tech Institutional Animal Care and Use
Committee.
3T3L1 cell culture, differentiation, and treatment
3T3L1 preadipocytes (ATCC CL-173, Manassas, VA,
USA) were cultured in basal media (DMEM media con-
taining 10% FBS, 100 units/ml penicillin, and 100 μg/ml
streptomycin (1× P/S)), at 37 °C in a humidiﬁed atmo-
sphere of 5% CO2
33–35. The media were replaced every
2 days until the cells became conﬂuent (day 0), and after 2
more days (day 2) the medium was changed to differ-
entiation medium I (DMEM with 10% FBS, P/S (1×),
IBMX (0.5 mM), dexamethasone (1 μM), insulin (1 μg/
ml), and rosiglitazone (2 μM)). At the end of day 4, the
medium was changed to differentiation medium II
(DMEM with 10% FBS, P/S (1×), and insulin (1 μg/ml)).
At the end of day 6, the medium was changed to basal
media and the cells were maintained until day 12. Pre-
adipocytes without differentiation induction were main-
tained in basal media and supplied with fresh medium
every 2 days till day 12. E2 at the concentrations of 1
nM–10 μM has been used to treat adipocytes69–76. Our
preliminary tests indicated that E2 at 1 nM, 10 nM, 0.1
μM, and 0.2 μM imposed similar effects, but E2 at 0.1 μM
(likewise 0.2 μM) was the most potent (data not shown).
As such, we used E2 of 0.1 μM for the treatments starting
on day 0 through day 12. Other chemicals were used at
the concentrations established previously, including PPT
(0.1 μM), DPN (0.1 μM), and baﬁlomycin A1 (4 nM), and
leupeptin (0.4 ng/ml)25,77,78, to treat the cells during
differentiation.
Primary stromal vascular cell culture, differentiation, and
treatment
Fresh gonadal WAT from C57BL/6J mice were dis-
sected, minced, and digested as previously described79.
Cells were suspended in basal media (DMEM/F12 con-
taining 10% FBS and 100 units/ml penicillin and 100 μg/
ml streptomycin (1× P/S)), and centrifuged at 500 × g for
5 min. The pellet was resuspended in basal media and
ﬁltered through a 40-micron cell strainer. After cen-
trifugation (500 × g) for 5 min, the pellet was resuspended
in basal media and plated on 10-cm dishes. After cell
subculture to a 95% conﬂuence (day 0) on 6-well plates,
differentiation was induced in differentiation medium
(DMEM/F12 medium with 10% FBS, 1× Pen/Strep, dex-
amethasone (5 μM), insulin (0.5 μg/ml), IBMX (0.5 mM),
and rosiglitazone (1 μM)) for 4 days (day 4). Then the cells
were maintained in maintenance medium (DMEM/F12
medium containing 10% FBS, 1× Pen/Strep, and insulin
(0.5 μg/ml)) for 6 days (day 10). The treatments with
chemicals (E2 at 0.1 μM, baﬁlomycin A1 at 4 nM, and
leupeptin at 0.4 ng/ml) started on day 0 through day 10 to
examine their effects on autophagy and adipogenesis.
Oil Red O staining
The Oil Red O working solution was freshly prepared by
mixing 0.35% stock solution with dH2O (6:4) and ﬁltered,
and the staining was conducted as described25,33,35. After
the media were removed, the cells were washed once with
cold phosphate buffered saline, and ﬁxed in 4% for-
maldehyde at room temperature for 10min. The cells
were then washed with dH2O and air dried. Oil Red O
working solution was added to start the staining at room
temperature for 1 h. The stained cells were washed with
dH2O for four times before the images were captured with
a Nikon ECLIPSE Ti Inverted Microscope (Melville, NY,
USA).
Autophagy ﬂux assay
To measure autophagy ﬂux in cultured cells, we treated
3T3L1 preadipocytes, stromal vascular cells, and mature
adipocytes (day 10) with baﬁlomycin A1 (inhibitor of
autophagosome acidiﬁcation, at 0.1 μM) plus leupeptin
(the inhibitor of lysosomal proteases, at 10 μg/ml) for 4 h.
The cells were then harvested to prepare cell lysates as
previously described25,33,35. To measure autophagy ﬂux in
WAT explants, freshly collected adipose tissues were
minced into small tissue fragments (2–3mm3) and cul-
tured for 4 h with DMEM medium supplemented with 2
mM glutamine, 1% (vol/vol) antibiotic solution, and 10%
(vol/vol) FBS in a CO2 incubator (37 °C, 5% CO2). The
WAT explant cultures in the presence or absence of
baﬁlomycin-A1 (0.1 μM) and leupeptin (10 μg/ml) were
then harvested and lysed as described previously25. The
turnover of LC3-II or p62 protein, i.e., the substrates of
autophagy for degradation, was measured by Western
blotting and image analysis to assess autophagy
ﬂux25,27,28.
Western blotting
Tissue and cell lysates were prepared with PLC lysis
buffer (30 mM Hepes, pH 7.5, 150mM NaCl, 10%
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glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA,
10mM NaPPi, 100mM NaF, 1 mM Na3VO4) supple-
mented with protease inhibitor cocktail (Roche), and 1
mM PMSF80. Total protein concentrations of the lysates
were determined using a DC protein assay kits (Bio-Rad).
Antibody (catalog number) information: GAPDH (MA5-
15738) and β-actin (MA5-15739) antibodies were pur-
chased from Pierce (Rockford, IL, USA); Atg5 (12994s),
Atg7 (8558s), Atg12 (2011s), p62 (5114s), p-mTOR
(Ser2448) antibody (5536s), and p-ULK1 (Ser757) anti-
body (14202s) from Cell Signaling Technology (Beverly,
MA, USA); Beclin 1 (MABN16), ERα (04–820), and ERβ
(GR39) antibodies from EMD Millipore (Billerica, MA,
USA); and LC3B antibody (L7543) from Sigma.
Statistical analysis
Data are presented as mean ± SD. Differences between
the groups were validated by one-way ANOVA with the
least signiﬁcant difference post hoc test to detect statis-
tical differences between groups and treatments (DI+ vs.
DI−, E2+ vs. E2−, and BL+ vs. BL−). Differences in
autophagy and adipose parameters between males and
females were validated by a t-test. A value of p < 0.05 was
considered statistically signiﬁcant.
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